A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

• Status: Terminated
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia (PHN).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan

Criteria

Inclusion Criteria:

• Postherpetic neuralgia with pain present for at least 9 months

Exclusion Criteria:

• Active herpes zoster skin rash

• Anticipated treatment for postherpetic neuralgia during the first 3 months of the study, including oral and topical medications, acupuncture, spinal cord stimulation, transcutaneous nerve stimulation (TNS), or trigger point injection

• Anticipated treatment with pain medication for the treatment of postherpetic neuralgia during the first 3 months of the study

• Use of capsaicin treatment for postherpetic neuralgia within 6 months, or anticipated use during the first 3 months of the study

• Use of botulinum toxin of any serotype for any reason within 6 months, or anticipated use during the study